Search Results

There are 6908331 results for: content related to: Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study

  1. You have free access to this content
    A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule

    International Journal of Geriatric Psychiatry

    Volume 22, Issue 5, May 2007, Pages: 456–467, Bengt Winblad, Jeffrey Cummings, Niels Andreasen, George Grossberg, Marco Onofrj, Carl Sadowsky, Stefanie Zechner, Jennifer Nagel and Roger Lane

    Article first published online : 22 MAR 2007, DOI: 10.1002/gps.1788

  2. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease

    International Journal of Clinical Practice

    Volume 65, Issue 4, April 2011, Pages: 465–471, G. T. Grossberg, J. T. Olin, M. Somogyi and X. Meng

    Article first published online : 11 FEB 2011, DOI: 10.1111/j.1742-1241.2011.02641.x

  3. You have free access to this content
    Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 4, August 2010, Pages: 246–253, Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez-Lage, Andreas Monsch, Magda Tsolaki and Teus Van Laar

    Article first published online : 29 MAR 2010, DOI: 10.1111/j.1755-5949.2010.00141.x

  4. You have free access to this content
    Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease

    International Journal of Clinical Practice

    Volume 69, Issue 5, May 2015, Pages: 518–530, G. Alva, J. L. Cummings, J. E. Galvin, X. Meng and D. M. Velting

    Article first published online : 16 FEB 2015, DOI: 10.1111/ijcp.12621

  5. Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch

    The Journal of Clinical Pharmacology

    Volume 49, Issue 4, April 2009, Pages: 430–443, Dr Gilbert Lefèvre, Ms Monika Büche, Dr Greg Sedek, Mr Steve Maton, Dr Albert Enz, Dr Ulrike Lorch, Dr Cyriaque Sagan and Dr Silke Appel-Dingemanse

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008330161

  6. Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 2, February 2008, Pages: 246–252, Dr Gilbert Lefèvre, Mrs Françoise Pommier, Dr Greg Sędek, Dr Mark Allison, Dr Hsun-Lun Aaron Huang, Mrs Beate Kiese, Dr Yu-Yun Ho and Dr Silke Appel-Dingemanse

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270007312154

  7. Identification of responders and reactive domains to rivastigmine in Alzheimer's disease

    Pharmacoepidemiology and Drug Safety

    Volume 16, Issue 5, May 2007, Pages: 545–551, S. V. Frankfort, B. A. Appels, A. de Boer, L. R. Tulner, J. P. C. M. van Campen, C. H. W. Koks, J. H. Beijnen and B. A. Schmand

    Article first published online : 16 NOV 2006, DOI: 10.1002/pds.1345

  8. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

    International Journal of Clinical Practice

    Volume 60, Issue 1, January 2006, Pages: 110–118, T. Dantoine, 1 S. Auriacombe, 2 M. Sarazin, 3 H. Becker, 4 J-J Pere and 5 I. Bourdeix 5

    Article first published online : 20 DEC 2005, DOI: 10.1111/j.1368-5031.2005.00769.x

  9. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease

    International Journal of Geriatric Psychiatry

    Volume 19, Issue 3, March 2004, Pages: 243–249, A. Burns, R. Spiegel and P. Quarg

    Article first published online : 13 FEB 2004, DOI: 10.1002/gps.1058

  10. Absorption of Rivastigmine from Different Regions of the Gastrointestinal Tract in Humans

    The Journal of Clinical Pharmacology

    Volume 44, Issue 6, June 2004, Pages: 599–604, Dr. Lucy Lee, Dr. Mohammad Hossain, Dr. Yanfeng Wang and Dr. Greg Sedek

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270004265645

  11. Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 20, Issue 1, January 2000, Pages: 1–12, Michael W. Jann

    Article first published online : 17 JAN 2012, DOI: 10.1592/phco.20.1.1.34664

  12. Rivastigmine for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline S Birks, Lee Yee Chong and John Grimley Evans

    Published Online : 22 SEP 2015, DOI: 10.1002/14651858.CD001191.pub4

  13. You have free access to this content
    Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies

    Drug Development Research

    Volume 64, Issue 1, January 2005, Pages: 71–81, Ramesh C. Gupta and A. Dekundy

    Article first published online : 19 APR 2005, DOI: 10.1002/ddr.10422

  14. Donepezil- or rivastigmine-induced acetylcholinesterase inactivation is not modulated by neramexane in rat brain

    Drug Development Research

    Volume 68, Issue 5, August 2007, Pages: 253–260, Ramesh C. Gupta and Andrzej Dekundy

    Article first published online : 13 NOV 2007, DOI: 10.1002/ddr.20186

  15. Treatment of Alzheimer's Disease (With or Without Cerebrovascular Disease)

    Evidence-based Dementia Practice

    Lon S. Schneider, Nawab Qizilbash, Mary Sano, Fadi Massoud, Jeffrey Kaye, Jason T. Olin, Knut Laake, Anne Rita Øksengaard, Barry S. Oken, Kristine Yaffe, Kentaro Hashimoto, Jesus López-Arrieta, John C. S. Breitner, Leon Flicker, Kenneth Rockwood, Josẽ Luísrodríquez-Martin, Pages: 467–588, 2008

    Published Online : 14 JAN 2008, DOI: 10.1002/9780470752340.ch34

  16. Pharmacokinetics of a Rivastigmine Transdermal Patch Formulation in Healthy Volunteers: Relative Effects of Body Site Application

    The Journal of Clinical Pharmacology

    Volume 47, Issue 4, April 2007, Pages: 471–478, Dr Gilbert Lefèvre, Dr Greg Sędek, Dr Hsun-Lun Aaron Huang, Dr Marc Saltzman, Dr Mitchell Rosenberg, Dr Beate Kiese and Dr Peter Fordham

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270006297748

  17. Risk of Pneumonia in New Users of Cholinesterase Inhibitors for Dementia

    Journal of the American Geriatrics Society

    Volume 63, Issue 5, May 2015, Pages: 869–876, Edward Chia-Cheng Lai, Monera B. Wong, Isao Iwata, Yinghong Zhang, Cheng-Yang Hsieh, Yea-Huei Kao Yang and Soko Setoguchi

    Article first published online : 27 APR 2015, DOI: 10.1111/jgs.13380

  18. Development of a capillary electrophoresis-mass spectrometry method for the determination of rivastigmine in human plasma – Optimization of the limits of detection and quantitation

    ELECTROPHORESIS

    Volume 33, Issue 4, February 2012, Pages: 644–652, Irene N. Nicolaou and Constantina P. Kapnissi-Christodoulou

    Article first published online : 27 MAR 2012, DOI: 10.1002/elps.201100286

  19. A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry

    Biomedical Chromatography

    Volume 18, Issue 3, April 2004, Pages: 160–166, Albert Enz, Alain Chappuis and Andre Dattler

    Article first published online : 11 DEC 2003, DOI: 10.1002/bmc.304

  20. You have free access to this content
    Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease Dementia

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 6, December 2010, Pages: 330–336, Frederick A. Schmitt, Martin R. Farlow, Xiangyi Meng, Sibel Tekin and Jason T. Olin

    Article first published online : 15 OCT 2010, DOI: 10.1111/j.1755-5949.2010.00182.x